Effects of tanshinone VI on phosphorylation of ERK and Akt in isolated cardiomyocytes and cardiac fibroblasts

European Journal of Pharmacology

Volumn 580, Issue 3, 2008, Pages 298-305

  Arino, Toru ^a   Tanonaka, Kouichi ^a   Kawahara, Yuji ^a   Maki, Toshiyuki ^a   Takagi, Norio ^a   Yagi, Akira ^b   Takeo, Satoshi ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b FUKUYAMA UNIVERSITY   (Japan)

Author keywords

Akt; Cardiac fibrosis; Cardiac hypertrophy; ERK; Tanshinone VI

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ENDOTHELIN 1; LEUCINE; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SOMATOMEDIN C; TANSHINONE; TANSHINONE VI; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL CELL; ARTICLE; ATTENUATION; CELL CULTURE; DRUG EFFECT; FEMALE; FIBROBLAST; HEART FIBROBLAST; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; MALE; NEWBORN; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RAT;

ANDROSTADIENES; ANIMALS; ATRIAL NATRIURETIC FACTOR; BLOTTING, WESTERN; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FIBROBLASTS; FLAVONOIDS; INSULIN-LIKE GROWTH FACTOR I; LEUCINE; MALE; MOLECULAR STRUCTURE; MYOCYTES, CARDIAC; PHENANTHRENES; PHOSPHORYLATION; PROLINE; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 38349094832     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.11.017     Document Type: Article

References (37)

1. Chen Z. Chinese traditional medicines. Some recent studies of Chinese medical plants. Kagaku no Ryoiki 35 (1981) 494-501
2. Cluzeaut F., and Maurer-Schultze B. Proliferation of cardiomyocytes and interstitial cells in the cardiac muscle of the mouse during pre- and postnatal development. Cell Tissue Kinet. 19 (1986) 267-274
3. Condorelli G., Drusco A., Stassi G., Bellacosa A., Roncarati R., Iaccarino G., Russo M.A., Gu Y., Dalton N., Chung C., Latronico M.V., Napoli C., Sadoshima J., Croce C.M., and Ross Jr. J. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 12333-12338
4. Diez C., Nestler M., Friedrich U., Vieth M., Stolte M., Hu K., Hoppe J., and Simm A. Down-regulation of Akt/PKB in senescent cardiac fibroblasts impairs PDGF-induced cell proliferation. Cardiovasc. Res. 49 (2001) 731-740
5. El Jamali A., Freund C., Rechner C., Scheidereit C., Dietz R., and Bergmann M.W. Reoxygenation after severe hypoxia induces cardiomyocyte hypertrophy in vitro: activation of CREB downstream of GSK3β. FASEB J. 18 (2004) 1096-1098
6. Feldman A.M., Weinberg E.O., Ray P.E., and Lorell B.H. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ. Res. 73 (1993) 184-192
7. Fernandez-Alfonso M.S., Ganten D., and Paul M. Mechanisms of cardiac growth. The role of the renin-angiotensin system. Basic Res. Cardiol. 87 Suppl 2 (1992) 173-181
8. Franke T.F., Yang S.I., Chan T.O., Datta K., Kazlauskas A., Morrison D.K., Kaplan D.R., and Tsichlis P.N. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81 (1995) 727-736
9. Fujio Y., Nguyen T., Wencker D., Kitsis R.N., and Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 101 (2000) 660-667
10. Goto K. Basic and therapeutic relevance of endothelin-mediated regulation. Biol. Pharm. Bull. 24 (2001) 1219-1230
11. Huang X., Yang B., Huang H., Xu Y., and Hu Z. Studies on the active principles of Dan-Shen III. Search for plant resources containing tanshinone II-A. Biol. Pharm. Bull. 22 (1980) 98-100
12. Kim J., Eckhart A.D., Eguchi S., and Koch W.J. Beta-adrenergic receptor-mediated DNA synthesis in cardiac fibroblasts is dependent on transactivation of the epidermal growth factor receptor and subsequent activation of extracellular signal-regulated kinases. J. Biol. Chem. 277 (2002) 32116-32123
13. Komuro I., Kudo S., Yamazaki T., Zou Y., Shiojima I., and Yazaki Y. Mechanical stretch activates the stress-activated protein kinases in cardiac myocytes. FASEB J. 10 (1996) 631-636
14. Lei X.L., and Chiou G.C. Cardiovascular pharmacology of Panax notoginseng (Burk) F.H. Chen and Salvia miltiorrhiza. Am. J. Chin. Med. 14 (1986) 145-152
15. Maki T., Horio T., Yoshihara F., Suga S., Takeo S., Matsuo H., and Kangawa K. Effect of neutral endopeptidase inhibitor on endogenous atrial natriuretic peptide as a paracrine factor in cultured cardiac fibroblasts. Br. J. Pharmacol. 131 (2000) 1204-1210
16. Maki T., Kawahara Y., Tanonaka K., Yagi A., and Takeo S. Effects of tanshinone VI on the hypertrophy of cardiac myocytes and fibrosis of cardiac fibroblasts of neonatal rats. Planta Med. 68 (2002) 1103-1107
17. Morisco C., Zebrowski D., Condorelli G., Tsichlis P., Vatner S.F., and Sadoshima J. The Akt-glycogen synthase kinase 3β pathway regulates transcription of atrial natriuretic factor induced by β-adrenergic receptor stimulation in cardiac myocytes. J. Biol. Chem. 275 (2000) 14466-14475
18. 2+/calmodulin-dependent transactivation of epidermal growth factor receptor. Circ. Res. 82 (1998) 1338-1348
19. Nakamura K., Fushimi K., Kouchi H., Mihara K., Miyazaki M., Ohe T., and Namba M. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 98 (1998) 794-799
20. Ogawa T., Bruneau B.G., Yokota N., de Bold M.L., and de Bold A.J. Tissue-specific regulation of renal and cardiac atrial natriuretic factor gene expression in deoxycorticosterone acetate-salt rats. Hypertension 30 (1997) 1342-1347
21. Ohki R., Yamamoto K., Ueno S., Mano H., Ikeda U., and Shimada K. Effects of olmesartan, an angiotensin II receptor blocker, on mechanically-modulated genes in cardiac myocytes. Cardiovasc. Drugs Ther. 17 (2003) 231-236
22. Okamura N., Kobayashi K., Yagi A., Kitazawa T., and Shimomura K. High-performance liquid chromatography of abietane-type compounds. J. Chromatogr. 542 (1991) 317-326
23. Papakrivopoulou J., Lindahl G.E., Bishop J.E., and Laurent G.J. Differential roles of extracellular signal-regulated kinase 1/2 and p38MAPK in mechanical load-induced procollagen alpha1(I) gene expression in cardiac fibroblasts. Cardiovasc. Res. 61 (2004) 736-744
24. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc. Res. 63 (2004) 423-432
25. Ross Jr. J., and Hongo M. The role of hypertrophy and growth factors in heart failure. J. Card. Fail. 2 Suppl (1996) S121-S128
26. Sano M., Fukuda K., Sato T., Kawaguchi H., Suematsu M., Matsuda S., Koyasu S., Matsui H., Yamauchi-Takihara K., Harada M., Saito Y., and Ogawa S. ERK and p38 MAPK, but not NF-kappaB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts. Circ. Res. 89 (2001) 661-669
27. Seimi S.K., Seinosuke K., Tsuyoshi S., Tomomi U., Tetsuaki H., Miki K., Ryuji T., Kenji I., and Mitsuhiro Y. Glycogen synthase kinase-3β is involved in the process of myocardial hypertrophy stimulated by insulin-like growth factor-1. Circ. J. 68 (2004) 247-253
28. Servant M.J., Giasson E., and Meloche S. Inhibition of growth factor-induced protein synthesis by a selective MEK inhibitor in aortic smooth muscle cells. J. Biol. Chem. 271 (1996) 16047-16052
29. Sharma H.S., van Heugten H.A., Goedbloed M.A., Verdouw P.D., and Lamers J.M. Angiotensin II induced expression of transcription factors precedes increase in transforming growth factor-beta 1 mRNA in neonatal cardiac fibroblasts. Biochem. Biophys. Res. Commun. 205 (1994) 105-112
30. Takahashi M., Tanonaka K., Yoshida H., Oikawa R., Koshimizu M., Daicho T., Toyo-Oka T., and Takeo S. Effects of ACE inhibitor and AT1 blocker on dystrophin-related proteins and calpain in failing heart. Cardiovasc. Res. 65 (2005) 356-365
31. Tanonaka K., Yoshida H., Toga W., Furuhama K., and Takeo S. Myocardial heat shock proteins during the development of heart failure. Biochem. Biophys. Res. Commun. 283 (2001) 520-525
32. Tsujita Y., Muraski J., Shiraishi I., Kato T., Kajstura J., Anversa P., and Sussman M.A. Nuclear targeting of Akt antagonizes aspects of cardiomyocyte hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 11946-11951
33. Wang A.M., Sha S.H., Lesniak W., and Schacht J. Tanshinone (Salviae miltiorrhizae extract) preparations attenuate aminoglycoside-induced free radical formation in vitro and cytotoxicity in vivo. Antimicrob. Agents Chemother. 47 (2003) 1836-1841
34. Weber K.T., Janicki J.S., Pick R., Capasso J., and Anversa P. Myocardial fibrosis and pathologic hypertrophy in the rat with renovascular hypertension. Am. J. Cardiol. 65 (1990) 1G-7G
35. Yagi A., Fujimoto K., Tanonaka K., Hirai K., and Takeo S. Possible active components of tan-shen (Salvia miltiorrhiza) for protection of the myocardium against ischemia-induced derangements. Planta Med. 55 (1989) 51-54
36. Zhao B.L., Jiang W., Zhao Y., Hou J.W., and Xin W.J. Scavenging effects of Salvia miltiorrhiza on free radicals and its protection for myocardial mitochondrial membranes from ischemia-reperfusion injury. Biochem. Mol. Biol. Int. 38 (1996) 1171-1182
37. Zhou G.Y., Zhao B.L., Hou J.W., Ma G.E., and Xin W.J. Protective effects of sodium tanshinone IIA sulphonate against adriamycin-induced lipid peroxidation in mice hearts in vivo and in vitro. Pharmacol. Res. 40 (1999) 487-491